- Home
- ATRC vs MDXG Comparison
ATRC vs MDXG Comparison
Compare ATRC & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRC
- MDXG
- Stock Information
- Founded
- ATRC 2000
- MDXG 2006
- Country
- ATRC United States
- MDXG United States
- Employees
- ATRC N/A
- MDXG N/A
- Industry
- ATRC Medical/Dental Instruments
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- ATRC Health Care
- MDXG Health Care
- Exchange
- ATRC Nasdaq
- MDXG Nasdaq
- Market Cap
- ATRC 1.1B
- MDXG 1.3B
- IPO Year
- ATRC 2005
- MDXG N/A
- Fundamental
- Price
- ATRC $39.84
- MDXG $8.57
- Analyst Decision
- ATRC Strong Buy
- MDXG Strong Buy
- Analyst Count
- ATRC 9
- MDXG 5
- Target Price
- ATRC $43.00
- MDXG $12.00
- AVG Volume (30 Days)
- ATRC 618.4K
- MDXG 617.6K
- Earning Date
- ATRC 02-12-2025
- MDXG 02-26-2025
- Dividend Yield
- ATRC N/A
- MDXG N/A
- EPS Growth
- ATRC N/A
- MDXG N/A
- EPS
- ATRC N/A
- MDXG 0.52
- Revenue
- ATRC $447,573,000.00
- MDXG $342,804,000.00
- Revenue This Year
- ATRC $18.02
- MDXG $9.56
- Revenue Next Year
- ATRC $12.93
- MDXG $9.19
- P/E Ratio
- ATRC N/A
- MDXG $16.49
- Revenue Growth
- ATRC 17.56
- MDXG 10.93
- 52 Week Low
- ATRC $18.94
- MDXG $5.47
- 52 Week High
- ATRC $43.11
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- ATRC 61.66
- MDXG 41.31
- Support Level
- ATRC $39.71
- MDXG $8.29
- Resistance Level
- ATRC $43.11
- MDXG $9.30
- Average True Range (ATR)
- ATRC 1.86
- MDXG 0.30
- MACD
- ATRC 0.15
- MDXG -0.04
- Stochastic Oscillator
- ATRC 63.10
- MDXG 27.10
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.